Navigation Links
Abbott Announces Positive One-Year Results from the World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
Date:10/22/2007

One-Year Data on First 30 Patients Enrolled in Ongoing Study Presented at

TCT

WASHINGTON, Oct. 22 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced continued positive results from ABSORB, the world's first clinical trial evaluating the safety and performance of a fully bioabsorbable drug eluting stent platform for the treatment of coronary artery disease. One-year results from the first 30 patients in the trial demonstrated no stent thrombosis and a low major adverse cardiac event (MACE) rate at 12 months (1 patient, 3.4%, n=29), with no additional MACE, including no re-treatment of a diseased lesion (ischemia-driven target lesion revascularization) since six months for patients who received a bioabsorbable stent. The overall MACE rate in the ABSORB trial at six months was 3.3%, as previously announced in March 2007. The results were presented today at the Cardiovascular Research Foundation's 19th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

"We continue to see consistent positive data from consecutive patient follow-up in the ABSORB trial," said Patrick W. Serruys, M.D., Ph.D., professor of interventional cardiology at the Thoraxcentre, Erasmus University Hospital, Rotterdam, and co-principal investigator in the ABSORB study. "Abbott's bioabsorbable coronary artery stent technology has maintained initial safety and effectiveness results in patients out to one year."

Abbott is the only company with a bioabsorbable drug eluting coronary stent in clinical trials. Abbott's bioabsorbable everolimus eluting coronary stent is made of polylactic acid, a proven biocompatible material that is commonly used in medical implants such as dissolvable sutures. As with a metallic stent, Abbott's bioabsorbable stent is designed to restore blood flow by propping a clogged vessel open, and to provide support until the blood vessel heals. Unlike a metallic stent, however, a bioabsorbable stent is designed to be slowly metabolized by the body and completely absorbed over time.

As reported in March 2007, late loss, a measure of reduction in lumen (vessel) diameter after stenting, was 0.44 mm for ABSORB at six months.

"ABSORB is an exciting future generation device that has the potential to advance the treatment of coronary artery disease beyond the benefits that next-generation metallic drug eluting stent platforms can provide," said John M. Capek, PhD., executive vice president, Medical Devices, Abbott. "Positive data with Abbott's bioabsorbable technology is encouraging and supports the direction we are moving toward in helping physicians open blocked arteries with stents, while also allowing the stent itself to disappear over time."

About the ABSORB Clinical Trial

The ABSORB trial is a prospective, non-randomized (open label) study designed to enroll up to 60 patients in Belgium, Denmark, France, New Zealand, Poland and The Netherlands. Key endpoints of the study include assessments of safety -- MACE (defined as any event that resulted in re-treatment of a diseased artery, heart attack or cardiac death) and stent thrombosis (blood clot formation) rates -- at 30,180 and 270 days, with additional annual follow-up for up to five years, as well as an assessment of the acute performance of the bioabsorbable drug-eluting stent. Other key endpoints of the study include successful deployment of the bioabsorbable drug eluting stent, follow-up measurements assessed by angiography, intravascular ultrasound (IVUS), and state-of-the-art imaging modalities at 180 days and two years.

For images of Abbott's bioabsorbable stent and other information, please visit the company's online TCT newsroom at http://www.abbottvascular.com/presskit.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products that are recognized internationally for their safety and effectiveness in treating patients with vascular disease.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
4. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
5. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
6. Abbott Researchers Focus on New Cutting-Edge Approaches in the Fight Against Cancer
7. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke
8. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
9. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
10. Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiologys 56th Annual Scientific Session
11. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... The U.S. cannabis market is growing ... use in 2016. According to a new report published by ... estimated $7.2 billion in 2016 and is projected to grow ... recreational sales are projected to jump from $2.6 billion in ... The market may grow faster as the estimate was based ...
(Date:2/23/2017)... , Feb. 22, 2017 This report analyzes analyzes the ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... and forecasts are provided for the period 2015 through 2022. ... Market data and analytics are derived from primary and secondary ...
(Date:2/23/2017)... Ill. , Feb. 23, 2017 Takeda ... subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502) and Cognition ... PLC and Ctrl Group Limited, announced a collaboration to ... an Apple Watch wearable to monitor and assess cognitive ... Depression (MDD) is the leading cause of disability ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... 22, 2017 , ... The National Academy of Certified Care ... April 2017 testing period. NACCM, a nonprofit organization, has provided the premier certification ... is periodically re-calibrated to ensure that newly certified professionals are prepared to work ...
(Date:2/22/2017)... ... February 22, 2017 , ... Giving patients with diabetes ... emergency room, fewer hospital admissions, and better blood pressure and glycemic control, a ... The study can be found here . , The study comes as ...
(Date:2/22/2017)... ... February 22, 2017 , ... In a 2012 survey, over ... not filling a prescription because they could not afford to pay for it. ... were 30-60%*. At the same time, hospitals, pharmacies, manufacturers and nursing ...
(Date:2/22/2017)... CA (PRWEB) , ... February 22, 2017 , ... Doctors ... recent addition of esteemed ophthalmologist, Dr. Steven H. Rauchman, practicing at North Valley ... in auto accidents, product liability, premise liability and other personal injury cases. These ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... newest advanced absorption cannabidiol (CBD) serum, “NANOCALM 300” Microemulsified Hemp Extract. This ... instant absorption from the mouth into the bloodstream. Far outpacing the ...
Breaking Medicine News(10 mins):